Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative

Drug Metabolism and Disposition

Volumn 31, Issue 9, 2003, Pages 1170-1175

  Luo, Gang ^a,f   Lin, Jianrong ^d   Fiske, William D ^a   Dai, Renke ^a   Yang, Tian J ^a   Kim, Sean ^a   Sinz, Michael ^a   Lecluyse, Edward ^c   Solon, Eric ^d   Brennan, James M ^e   Benedek, Irma H ^f   Jolley, Summer ^c   Gilbert, Darryl ^c   Wang, Lifei ^a   Lee, Frank W ^b   Gan, Liang Shang ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d Quest Pharmaceutical Services   (United States)

^e Innaphase Corporation   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450 3A4; DEXAMETHASONE; DIMETHYL SULFOXIDE; DPC 681; N [(3 FLUOROPHENYL)METHYL]GLYCYL N [3 [[(3 AMINOPHENYL)SULFONYL] 2 (AMINOPHENYL)AMINO] 2 HYDROXY 1 (PHENYLMETHYL)PROPYL] 3 METHYLVALINAMIDE; PROTEINASE INHIBITOR; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INDUCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLOTTING; LIVER CELL CULTURE; MALE; NONHUMAN; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; RAT; VIRUS INHIBITION;

ANIMALS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DIMETHYL SULFOXIDE; ENZYME INDUCTION; FEMALE; HALF-LIFE; HEPATOCYTES; HIV PROTEASE INHIBITORS; HUMANS; MALE; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; RATS, SPRAGUE-DAWLEY; RIFAMPIN; RITONAVIR; STEROID HYDROXYLASES; SULFONAMIDES; TIME FACTORS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 10744229689     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.9.1170     Document Type: Article

References (33)

1. Barry M, Mulcahy F, Merry C, Gibbons S, and Back D (1999) Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 36:289-304.
2. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, and Berkenstam A (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 95:12208-12213.
3. Czerwinski M, Opdam P, Madan A, Carroll K, Mudra D, Gan L, Luo G, and Parkinson A (2002) Analysis of CYP mRNAs expression by branched DNA technology. Methods Enzymol 357:170-179.
4. Eagling V, Back D, and Barry M (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194.
5. Geick A, Eichelbaum M, and Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587.
6. Greiner B, Eichelbaum M, Fritz P, Kreichgauer H, von Richter O, Zundler J, and Kroemer H (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Investig 104:147-153.
7. Hennessy M, Kelleher D, Spiers J, Barry M, Kavanagh P, Back D, Mulcahy F, and Feely J (2001) St. Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 53:75-82.
8. Hoen P, Commandeur J, Vermeulen N, Van Berkel T, and Bijsterbosch M (2000) Selective induction of cytochrome P450 3A1 by dexamethasone in cultured rat hepatocytes: analysis with a novel reverse transcriptase-polymerase chain reaction assay section sign. Biochem Pharmacol 60:1509-1518.
9. Hsu A, Granneman G, Witt G, Locke C, Denissen J, Molla A, Valdes J, Smith J, Erdman K, Lyons N, et al. (1997) Multiple-dose pharmacokineties of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 41:898-905.
10. Huss J and Kasper C (1998) Nuclear receptor involvement in the regulation of rat cytochrome P450 3A23 expression. J Biol Chem 273:16155-16162.
11. Johnson T, Tanner M, and Tucker G (2000) A comparison of the ontogeny of enterocytic and hepatic cytochromes P450 3A in the rat. Biochem Pharmacol 60:1601-1610.
12. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J, and Gerber N (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26:552-561.
13. Kumar G, Dykstra J, Roberts E, Jayanti V, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, and Granneman G (1999) Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos 27:902-908.
14. Kumar G, Rodrigues A, Buko A, and Denissen J (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423-431.
15. LeCluyse E, Bullock P, Parkinson A, and Hochman J (1996). Cultured rat hepatocytes, in Models for Assessing Drug Absorption and Metabolism, Pleunu Press, New York,
16. LeCluyse E, Madan A, Hamilton G, Carroll K, DeHaan R, and Parkinson A (2000) Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14:177-188.
17. Ledirac N, de Sousa G, Fontaine F, Agouridas C, Gugenheim J, Lorenzon G, and Rahmani R (2000) Effects of macrolide antibiotics on CYP3A expression in human and rat hepatocytes: interspecies differences in response to troleandomycin, Drug Metab Dispos 28:1391-1393.
18. Lehmann J, McKee D, Watson M, Willson T, Moore J, and Kliewer S (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Investig 102:1016-1023.
19. Li A, Roque M, Beck D, and Kaminski D (1992) Isolation and culturing of hepatocytes from human livers. J Tissue Cult Methods 14:139-146.
20. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, et al. (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes, Drug Metab Dispos 30:795-804.
21. Mahnke A, Strotkamp D, Roos P, Hanstein W, Chabot G, and Nef P (1997) Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver. Arch Biochem Biophys 337:62-68.
22. Mayhew B, Jones D, and Hall S (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031-1037.
23. Molla A, Granneman G, Sun E, and Kempf D (1998) Recent developments in HIV protease inhibitor therapy. Antiviral Res 39:1-23.
24. Moore L, Maglich J, McKee D, Wisely B, Willson T, Kliewer S, Lambert M, and Moore J (2002) Pregnane X receptor (PXR), constitutive androstane receptor (CAR) and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 16:977-986.
25. Pearce R, McIntyre C, Madan A, Sanzgiri U, Draper A, Bullock P, Cook D, Burton L, Latham J, Nevins C, and Parkinson A (1996) Effects of freezing, thawing and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 331:145-169.
26. Perloff M, Von Moltke L, Marchand J, and Greenblatt D (2001) Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRPI) expression and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci 90:1829-1837.
27. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G, and Maurel P (1990) Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18:595-606.
28. Robertson G, Farrell G, and Liddle C (1998) Sexually dimorphic expression of rat CYP3A9 and CYP3A18 genes is regulated by growth hormone. Biochem Biophys Res Commun 242:57-60.
29. Smith P, DiCenzo R, and Morse G (2001) Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 40:893-905.
30. Solon E, Balani S, Luo G, Yang T, Haines P, Wang L, Demond T, Diamond S, Christ D, Gan L, and Lee F (2002) Interaction of ritonavir on tissue distribution of a [14C]L-valinamide. a potent HIV-1 protease inhibitor, in rats using quantitative whole-body autoradiography. Drug Metab Dispos 30:1164-1169.
31. Tran J, Gerber J, and Kerr B (2001) Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 40:207-226.
32. Troutman M, Luo G, Gan L, and Thakker D eds (2001). The role of p-glycoprotein in drug disposition: significance to drug development, in Drug-Drug Interaction, Marcel Dekker, Inc., New York.
33. Xie W, Barwick J, Simon C, Pierce A, Safe S, Blumberg B, Guzelian P, and Evans R (2000) Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev 14:3014-3023.